Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Batist

Showing results (111-120 of 165) with videos related to

Pageof 17
Sort By:
Oncogene|April 20, 2002
Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cellsAla-Eddin Al Moustafa, Moulay A Alaoui-Jamali, Gerald Batist, et al.
Cancer Medicine|March 31, 2018
The importance of greater speed in drug development for advanced malignanciesDavid J Stewart, Andrew A Stewart, Paul Wheatley-Price, et al.
Investigational New Drugs|September 1, 2005
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignanciesEric X Chen, Gerald Batist, Lillian L Siu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsGerald Batist, Karen A Gelmon, Kim N Chi, et al.
Molecular Cancer Therapeutics|July 30, 2009
Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapyMartin Loignon, Weimin Miao, Lianggao Hu, et al.
Scientific Reports|July 30, 2020
Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCRMiguel Alcaide, Matthew Cheung, Jack Hillman, et al.
Critical Reviews in Oncology/Hematology|May 7, 2010
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot studyMartine T E Puts, Johanne Monette, Veronique Girre, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in CanadaStephen Sundquist, Gerald Batist, Kathy Brodeur-Robb, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRIEric R Paquet, Jing Cui, David Davidson, et al.
Medecine Sciences : M/S|March 17, 2018
[Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria]Ouajdi Felfoul, Mahmood Mohammadi, Samira Taherkhani, et al.
Pageof 17

Showing results (111-120 of 165) with videos related to

Sort By:
Pageof 17
Oncogene|April 20, 2002
Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cellsAla-Eddin Al Moustafa, Moulay A Alaoui-Jamali, Gerald Batist, et al.
Cancer Medicine|March 31, 2018
The importance of greater speed in drug development for advanced malignanciesDavid J Stewart, Andrew A Stewart, Paul Wheatley-Price, et al.
Investigational New Drugs|September 1, 2005
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignanciesEric X Chen, Gerald Batist, Lillian L Siu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsGerald Batist, Karen A Gelmon, Kim N Chi, et al.
Molecular Cancer Therapeutics|July 30, 2009
Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapyMartin Loignon, Weimin Miao, Lianggao Hu, et al.
Scientific Reports|July 30, 2020
Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCRMiguel Alcaide, Matthew Cheung, Jack Hillman, et al.
Critical Reviews in Oncology/Hematology|May 7, 2010
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot studyMartine T E Puts, Johanne Monette, Veronique Girre, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in CanadaStephen Sundquist, Gerald Batist, Kathy Brodeur-Robb, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRIEric R Paquet, Jing Cui, David Davidson, et al.
Medecine Sciences : M/S|March 17, 2018
[Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria]Ouajdi Felfoul, Mahmood Mohammadi, Samira Taherkhani, et al.
Pageof 17